Not recommended if patient has risk factors for heart disease (high blood pressure, high cholesterol, obesity, diabetes, smoking, strong family history of heart disease, postmenopausal woman, or male >40 years of age). Cerebral/subarachnoid hemorrhage and stroke reported with 5-HT~1~ agonist administration. Nasal spray contraindicated in cerebrovascular syndromes. Elevated blood pressure reported on rare occasions with and without history of hypertension. Peripheral vascular ischemia and colonic ischemia reported with 5-HT~1~ agonists. Rarely, partial vision loss and blindness (transient and permanent) reported with 5-HT~1~ agonists. Should not be given to patients who have risk factors for CAD (e.g. hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of CAD, menopause, male >40 years of age) without adequate cardiac evaluation. Use with caution in hepatic impairment (drug clearance may be reduced leading to increased plasma concentrations). Symptoms of agitation, confusion, hallucinations, hyper-reflexia, myoclonus, shivering, and tachycardia may occur with concomitant proserotonergic drugs (e.g. SSRIs/SNRIs or triptans) or agents which reduce metabolism of zolmitriptan. Concurrent use of serotonin precursors not recommended. Some products (tablets) contain phenylalanine. Only indicated for treatment of acute migraine. Not intended to prevent or reduce number of migraine attacks.